Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2020-04-01 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
2019年度财务决算报告
Annual Report Classification · 100% confidence The document is titled '2019 年度财务决算报告' which translates to '2019 Annual Financial Settlement Report'. It contains detailed financial data including income, profit, assets, liabilities, cash flow, and explanatory notes for the fiscal year 2019. The length is over 10,000 characters, indicating a full report rather than a brief announcement. The content includes comprehensive financial statements and analysis typical of an annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2019
2020-04-01 Chinese
关于确认过往使用自有闲置资金购买理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Tianjin Ruipu Biotechnology Co., Ltd. regarding the confirmation of past use of idle funds to purchase financial products. It details the amounts, types, and terms of various financial products purchased with the company's own idle funds. The document includes board and supervisory opinions on the matter and confirms compliance with relevant stock exchange listing rules. There is no indication that this is a full financial report, audit report, or earnings release. It is not a call transcript, nor a management or governance report. The document is a formal announcement about the company's financial activities related to capital management and investment of idle funds, which fits best under Capital/Financing Update (CAP). The document length is 7636 characters, which is substantive and contains detailed financial data about the capital usage, not just a brief notice or a report publication announcement. Therefore, the classification is CAP with high confidence.
2020-04-01 Chinese
监事会关于2019年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board's opinion on the company's 2019 internal control self-evaluation report. It references regulatory requirements and internal control systems but does not contain full financial statements or detailed financial data. The document is a formal audit or review opinion on internal controls, which aligns with the definition of an Audit Report / Information (AR). The document length is short but contains substantive content beyond a mere announcement or certification, so it is not RPA or RNS. Therefore, the best classification is AR. FY 2019
2020-04-01 Chinese
关于授权公司使用部分闲置资金购买低风险理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding the authorization to use part of idle funds to purchase low-risk financial products. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, details the amount of idle raised funds and self-owned funds to be invested, and includes opinions from independent directors and the supervisory board. The document is about the company's financing and capital management activities, specifically the use of idle raised funds and self-owned funds for investment in low-risk financial products. It is not a full financial report, audit report, or earnings release, nor is it a regulatory filing or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it updates on the company's capital usage and financing activities related to idle funds investment. The document length is under 5,000 characters but contains substantive information about capital use, not just a brief announcement or report publication notice.
2020-04-01 Chinese
关于公司取得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of new veterinary drug registration certificates. It includes details about the certificates, the drugs, and their uses. There is no financial data, no mention of financial results, no regulatory certifications, or meeting materials. The document is an official announcement of a regulatory approval related to product registration, which does not fit into financial reports or management changes. It is a regulatory announcement about a company event that does not fall into other specific categories. Therefore, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit elsewhere.
2020-03-26 Chinese
关于公司取得兽药产品批准文号的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a veterinary drug product by the Ministry of Agriculture and Rural Affairs. It includes details about the product, its development, and significance for the company. The document is short (1005 characters) and does not contain financial data, management discussion, or regulatory certifications. It is an announcement of a specific company event (product approval) rather than a financial report or regulatory filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous company announcements that do not fit other specific categories.
2020-03-18 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.